Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis

Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S86-92. Epub 2013 Oct 4.

Abstract

Glucocorticoids are highly effective in treating polymyalgia rheumatica and giant cell arteritis, but their use is associated with numerous adverse events. Therefore, it is important to use them for the shortest period of time possible. The published evidence suggests that discontinuation of GC is feasible in a substantial number of patients with polymyalgia rheumatica and giant cell arteritis after an adequate period of treatment, provided that glucocorticoids are tapered gradually. Recurrences are relatively infrequent in polymyalgia rheumatica and somewhat more common in giant cell arteritis. Immunosuppressive agents may be used in patients with frequently relapsing or recurring disease to decrease exposure to glucocorticoids.

Publication types

  • Review

MeSH terms

  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Giant Cell Arteritis / diagnosis
  • Giant Cell Arteritis / drug therapy*
  • Giant Cell Arteritis / immunology
  • Glucocorticoids / administration & dosage*
  • Glucocorticoids / adverse effects
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Patient Selection
  • Polymyalgia Rheumatica / diagnosis
  • Polymyalgia Rheumatica / drug therapy*
  • Polymyalgia Rheumatica / immunology
  • Recurrence
  • Remission Induction
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Immunosuppressive Agents